AbbVie Inc (ABBV)vsAkso Health Group ADR (AHG)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
AHG
Akso Health Group ADR
$0.84
+14.93%
HEALTHCARE · Cap: $625.57M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 465389% more annual revenue ($64.39B vs $13.83M). ABBV leads profitability with a 9.8% profit margin vs -135.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
AHG
Avoid15
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
+10.2%
Fair Value
$1.57
Current Price
$0.84
$0.73 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -89.4% — below average capital efficiency
Revenue declined 12.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : AHG
The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : AHG
The primary concerns for AHG are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while AHG is a turnaround play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.28 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 15/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Akso Health Group ADR
HEALTHCARE · MEDICAL DISTRIBUTION · China
Akso Health Group ADR is a leading entity in the healthcare sector, dedicated to providing innovative medical solutions and comprehensive patient care services. With a strong emphasis on advanced health technologies, the company is strategically positioned in the telehealth and personalized medicine markets, supported by a robust research and development framework. As it navigates the rapidly evolving healthcare landscape, Akso Health Group presents an attractive investment opportunity for institutional investors seeking to capitalize on transformative trends within the industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?